CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BeBetter Med Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BeBetter Med Inc
Science City
Phone: +86 2032038086p:+86 2032038086 GUANGZHOU, GNG  510663  China Ticker: 688759688759
Business Summary
BeBetter Med Inc is a China-based company primarily engaged in independent research and development of innovative drugs. The Company mainly focuses on major disease areas such as oncology, autoimmune diseases, and metabolic diseases. The Company’s product pipelines mainly include BEBT-908, BEBT-209, BEBT-109, BEBT-260, BEBT-503, BEBT-305, BEBT-607, BEBT-507, BEBT-808, BEBT-809, BEBT-508, and BEBT-701. BEBT-908 has been approved for marketing. The Company primarily operates its businesses in the domestic market.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024-----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager ChanggengQian
Finance Director, Secretary of the Board TianyiZhang
Senior Deputy General Manager- Chemical Drug Discovery, Director XiongCai 1/1/2022 1/1/2021
Chief Scientific Officer, Deputy General Manager - Biopharmaceutical Discovery XinjianLiu
Deputy General Manager - Clinical Operations YajieCao

General Information
Number of Employees: 150 (As of 6/30/2025)
Outstanding Shares: 450,036,657 (As of 10/28/2025)
Stock Exchange: SHA
Fax Number: +86 2036657222


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 31, 2025